Please Wait...

Bioclinica Launches NAFLD/NASH Clinical Trials Practice

Helps sponsors apply medical imaging in trials to advance development of NAFLD/NASH therapeutics

April 18, 2019

PRINCETON, NJ – Bioclinica®, a leading provider of science and technology expertise to assist the life science industry in advancing the development of medical therapies, announced today that it has assembled a team of experts dedicated to nonalcoholic fatty liver disease (NAFLD) and its more advanced form, nonalcoholic steatohepatitis (NASH), to help sponsors develop therapeutics using medical imaging and other biomarkers in clinical trials.

NAFLD and NASH are increasing in prevalence, with nearly two billion people affected worldwide. "We've assembled a world-class team with a deep understanding of this disease space and the scientific, medical and regulatory intricacies of medical imaging endpoints for NAFLD and NASH trials to accelerate clinical development of effective treatments approved by international regulators," said Bioclinica President and CEO David Herron.

"Developing NAFLD and NASH therapeutics requires innovation in patient screening and monitoring in the clinical research setting," said Scientific Director Mark Tengowski, DVM, MS, PhD. "We're currently working with regulators and sponsors to successfully apply medical imaging as a reliable and non-invasive method of assessing liver fat and stiffness parameters. Our collective objective is to significantly reduce or replace the reliance on liver biopsies with non-invasive imaging methods to assess therapeutic response."

To date, Bioclinica has helped sponsors apply medical imaging to identify patients for inclusion in drug intervention trials and to monitor patient response at more than 225 investigator sites around the globe. "High-quality quantitative liver imaging is no easy task. Bioclinica MRI scientists and technologists work closely with the imaging facilities to qualify their equipment and train the staff on proper acquisition techniques," Tengowski explained adding, "These efforts combined with ongoing quality control ensure accurate, consistent, and reliable endpoints."

Bioclinica provides sponsors end-to-end NAFLD/NASH clinical trial support, beginning early in the protocol design process and extending through to regulatory submission. Services include infrastructure to submit, manage, analyze, report and transfer trial medical imaging data compliant with global data privacy and regulatory requirements using Bioclinica’s best-in-class SMART suite. Bioclinica drug safety experts are available to provide Risk Evaluation and Mitigation Strategies (REMS) as part of a comprehensive NAFLD/NASH offering.

Partnering with Bioclinica means sponsors can tap Bioclinica's extensive medical imaging capabilities employed on thousands of clinical trials, as well as the company’s experience supporting nearly 200 FDA regulatory approvals across a wide range of indications.

Bioclinica will be among the experts participating in and exhibiting at the third annual NASH Summit in Boston on April 22-25. Industry professionals involved in the conduct of NAFLD and NASH clinical trials are invited to join an informational webinar with Mark Tengowski on April 18,  Detection and Monitoring in Fatty Liver Clinical Trials: The Role of Medical Imaging.

About Bioclinica

Bioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. Through deep medical, scientific and technology expertise, the company provides medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments; clinical trial management software; and drug safety solutions. Bioclinica’s global team of life science experts serve more than 500 pharmaceutical, biotechnology and device organizations – including the top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

 

###

 

Media Contact
Nicole Klatsky
+1 (609) 865-5212

Learn more about Bioclinica at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Save time and minimize risk with Bioclinica’s Clinical Trial Management System (CTMS) Starter Package. A full-featu… https://t.co/MW4e031hXf
Bioclinica (20 hours ago)
Bioclinica’s Resale #IRT offers flexible configuration, delivery in weeks not months, & an affordable, predictable… https://t.co/vVjH0VLpSv
Bioclinica (5 days ago)
The Clinical Trial Management System (CTMS) Starter Package from Bioclinica saves time and minimizes the risk often… https://t.co/VRGMjKlzL4
Bioclinica (1 week ago)
We are pleased to announce @directbiologics will leverage Bioclinica's IRT solution for its EXIT #COVID19 study. Th… https://t.co/Iun6UrL6Bt
Bioclinica (2 weeks ago)
The integration of Bioclinica CTMS & eTMF with SharePoint enable teams to work in familiar programs & remote work a… https://t.co/QRBt1sdljh
Bioclinica (2 weeks ago)
Ready for a centralized view into your studies but don’t want to take on the risk of procuring a CTMS? With our rap… https://t.co/uognAzsgG3
Bioclinica (3 weeks ago)